Health Futures partners are thought leaders in the transformation of health systems. They provide valuable distribution networks, financial resources, and industry know-how to fuel health care innovation. In collaboration, they iterate and co-create with startups to improve how people access and pay for healthcare.
Leading with Excellence
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and inter-ventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across fifty countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
Healthcare systems around the world are amazingly complex. For healthcare to improve, it must be more broadly accessible; delivered more safely, quickly, and effectively; and a more satisfying experience for everyone involved. At Microsoft, we’re focused on the heroes of healthcare, the people developing new, safer, and more effective therapies, the people who provide treatment, the patients who receive it, and the administrators who make everything run smoothly.
Our role is to assist these heroes and augment what they do with our expertise in cloud, business processes, enterprise productivity, and Artificial Intelligence. We want to make their lives—and through them, the lives of all individuals—better.
Inspired by our founder, Dr Paul Janssen, we believe that scien-tific innovation is critical to better health outcomes for people in Asia Pacific and around the world. As a global leader in human health, we have an important role to play in addressing these significant medical needs. Our vision is to be a leader in transformational medical innovation. We aspire to improve global and local healthcare by always putting patients first and by discovering the delivering solutions that matter most to the people. Patients and families that we serve.
We have made a commitment to partnering with individuals and companies who share our vision and a key pillar of our approach to research and development in the region is our Asia Pacific Innovation Centre, launched in 2014 and located in Shanghai with satellite centres in Singapore, Australia and Japan.
We take a collaborative approach to research and development that fuels local entrepreneurship and scientific excellence including exploring new healthcare models related to fintech and insurtech with the aim of supporting the broader health ecosystem in the region.
Through the power of technology, Cisco empowers healthcare organizations to deliver innovative patient care, streamline workflows for care teams, optimize clinical and business operations, and facilitate security and compliance. With 20 years of experience working with providers, payers, device manufacturers, and pharmaceutical companies, our leadership is unmatched around the world. We empower innovation at more than 17,000 healthcare organizations in 118 countries. Every day, we push the boundaries of what is possible in healthcare. Our commitment to forward-thinking healthcare lays the foundation for tomorrow.
We help healthcare organizations achieve their desired business outcomes with SaaS offers, such as conferencing solutions for employees or patients and healthcare-specific solutions—such as Cisco Patient Connect and Extended Care—for personalization and collaboration. Our comprehensive portfolio fits any work environment, from the patient’s bedside to the doctor’s home, from the administrative back office to the research laboratory. Cisco delivers collaboration through the cloud, on site, or through a hybrid combination of the two, with always-on solutions that enable high-quality interactions among patients and care teams, scalability across facilities and branches, and end-to-end security.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
The Singapore Economic Development Board (EDB), a government agency under the Ministry of Trade and Industry, is responsible for strategies that enhance Singapore’s position as a global centre for business, innovation, and talent. We undertake investment promotion and industry development, and work with international businesses, both foreign and local, by providing information, connection to partners and access to government incentives for their investments. Our mission is to create sustainable economic growth, with vibrant business and good job opportunities for Singapore.
The Saw Swee Hock School of Public Health aims to continually foster healthier communities in Singapore and the region, and impact public health programmes and policies through its robust educational programmes and translational cross-disciplinary research work on cohort studies and life course epidemiology, infectious disease research, health technology assessments, health promotion, workplace safety and health, health systems evaluation and health services research. An interdisciplinary approach, augmented by rigorous training, applicable research and regional partnerships, places SSHSPH at the forefront of public health knowledge discovery and practice in Asia.
Founded in 2002, Ying is an integrated communications agency focused on helping clients bring their B2B stories to life in Asia. It was started with just two people who shared a love for the amazing innovations, exceptional engineering and industry-changing technology. Today, Ying is more than 40 strong in Singapore, delivering B2B marketing and B2B PR to some of the most innovative companies in the world. In 2017, it was acquired by New York-based Finn Partners, one of the fastest growing independent public relations agencies in the world. With more than 700 professionals, Finn Partners provides its clients with global access and capabilities through 18 offices across three continents. Finn Partners has an award-winning healthcare practice that works with some of the best-known names in the industry to help them convey value using skilled patient advocacy, traditional and digital media and policy support.
Anthill Ventures is a premier, global speed-scaling ecosystem for growth stage startups. Its unique ability is to source, invest, rapidly scale early-stage companies, subsequently enabling them to raise or syndicate funding within 12 to 18 months. Its dedicated team spread across Hyderabad, Mumbai, Bengaluru and Singapore enables the startups with an extensive global network of venture capitalists and investors, market access opportunities from corporates, and expertise from mentors and luminaries in the technology industry. Anthill Ventures primarily focuses on exciting technology startups in verticals such as healthtech, life sciences, media and entertainment, urbantech and smart cities.
Upjohn is a Pfizer division covering 20 iconic brands, operating with dedicated resources in more than 66 markets, 32 markets with direct commercial or medical presence and more than 34 alliance markets, and serving 54 million patients. Upjohn portfolio includes 20 industry-leading brands in the areas of cardiovascular disease, pain, urology, psychiatry, and other Non-Communicable Diseases (NCDs). Being a stand-alone division within Pfizer, Upjohn combines the agility of a start-up with the resources and capabilities of a Fortune 100 enterprise.